Abstract:Background: Gamma Knife Radiosurgery (GKRS), a specific type of Stereotactic Radiosurgery (SRS), has developed as a significant modality in the treatment of glioblastoma, particularly in conjunction with standard chemotherapy. The goal of this study is to evaluate the efficacy of combining GKRS with surgical resection and chemotherapy in enhancing therapeutic effects for glioblastoma patients aged 55 years and older. Methods: This prospective clinical study, conducted in accordance with the STROBE guidelines, involved 49 glioblastoma patients aged 55 years and older, treated between January 2013 and January 2023. Data were collected prospectively, and strict adherence to the STUPP protocol was maintained. Only patients who conformed to the STUPP protocol were included in the analysis. Due to concerns regarding the cognitive impairment associated with conventional radiotherapy, and at the patients' request, a radiosurgery plan was offered. Radiosurgery was administered for 4–8 weeks following surgical resection. Any patients who had not received previous radiotherapy received open surgical tumor removal, followed by GKRS along with adjuvant chemotherapy. Results: In this prospective clinical study of 49 glioblastoma patients aged 55 years and older, the average lifespan post-histopathological diagnosis was established at 22.3 months (95% CI: 12.0–28.0 months). The median time before disease progression was 14.3 months (95% CI: 13.0–29.7 months). The median duration until the first recurrence after treatment was 15.2 months, with documented cases varying between 4 and 33 months. The Gamma Knife Radiosurgery (GKRS) treatment involved a median marginal recommended dose of 12.5 Gy, targeting an average volume of 5.7 cm3 (range: 1.6–39 cm3). Local recurrence occurred in 21 patients, while distant recurrence was identified in 8 patients. Within the cohort, 34 patients were subjected to further therapeutic approaches, including reoperation, a second GKRS session, the administration of bevacizumab and irinotecan, and PCV chemotherapy. A cognitive function assessment revealed that the patients treated with GKRS experienced significantly less cognitive decline compared to the historical controls, who were treated with conventional radiotherapy. The median MMSE scores declined by 1.9 points over 12 months, and the median MoCA scores declined by 2.9 points. Conclusion: This study demonstrates that Gamma Knife Radiosurgery (GKRS), when integrated with surgical resection and adjuvant chemotherapy, offers a substantial benefit for glioblastoma patients aged 55 years and older. The data reveal that GKRS not only prolongs overall survival and progression-free survival but also significantly reduces cognitive decline compared to conventional radiotherapy. These findings underscore the efficacy and safety of GKRS, advocating for its incorporation into standard treatment protocols for older glioblastoma patients. The potential of GKRS to improve patient outcomes while preserving cognitive function is compelling and warrants further research to optimize and confirm its role in glioblastoma management.

Radt-31. Embracing Hypofractionated Radiotherapy For Glioblastoma In A Resource Constrained Setting

Radt-07. Hypofractionated Radiotherapy In Brainstem Gliomas- Experience From A Tertiary Care Centre In India

Ncog-03. Descriptive Analysis And Outcome Comparison Between Patients With Glioblastoma Multiforme Who Receive 15 Versus 30 Fractions Of Radiotherapy: A Retrospective Chart Review

Moderately Hypofractionated Radio(chemo)therapy With Simultaneous Integrated Boost for Recurrent, Previously Irradiated, High-grade Glioma

P18.36.A REGIONAL CENTRE EXPERIENCE OF LARGE PTV VOLUME PATIENT OUTCOMES WITH 40GY/15# RADIOTHERAPY FOR GLIOBLASTOMA MULTIFORME (GBM)

Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma

Radt-26. Radiation Fractionation In The Management Of Elderly Patients With Glioblastoma By Age

Hypofractionated Stereotactic Radiotherapy as a Salvage Therapy for Recurrent High-Grade Gliomas: Single-Center Experience

Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival

Survival and Prognostic Factors in Patients with Glioblastoma Multiforme Receiving Radiation and Temozolomide – A Retrospective Study

Qlti-18. Treatment And Outcomes Of Frail Patients With Newly Diagnosed High-Grade Gliomas: Should We Consider Changing Our Treatment Approach?

Efficacy and Cognitive Outcomes of Gamma Knife Radiosurgery in Glioblastoma Management for Elderly Patients

Radiotherapeutic advances in the management of glioblastoma

Radt-40. Evaluation Of Smaller Clinical Target Volumes And Patterns Of Progression In Patients With Newly Diagnosed Glioblastoma To Inform Future Directions In Radiation Treatment Planning

Multifocal high-grade glioma radiotherapy safety and efficacy

Hypofractionated re‐irradiation for diffuse intrinsic pontine glioma

Promising outcome of patients with recurrent glioblastoma after Gamma Knife-based hypofractionated radiotherapy

Safety of Inhomogeneous Dose Distribution IMRT for High-Grade Glioma Reirradiation: A Prospective Phase I/II Trial (GLIORAD TRIAL)

Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report

Radt-17. Fractionated Reirradiation Of Recurrent Idh Wildtype Glioblastoma: Higher Reirradiaiton Dose And Safety

Radt-34. Re-Irradiation Regimens For Recurrent Glioma: Survival And Toxicity